Eton Pharmaceuticals (NASDAQ:ETON) Insider Sells $229,421.62 in Stock

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) insider David Krempa sold 4,166 shares of the business’s stock in a transaction on Tuesday, October 6th. The shares were sold at an average price of $55.07, for a total transaction of $229,421.62. Following the sale, the insider owned 43,381 shares in the company, valued at approximately $2,388,991.67. This trade represents a 8.76% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link.

David Krempa also recently made the following trade(s):

• On Monday, August 24th, David Krempa sold 25,000 shares of Eton Pharmaceuticals stock. The stock was sold at an average price of $65.07, for a total transaction of $1,626,750.00.

Eton Pharmaceuticals Stock Down 0.2%

Shares of Eton Pharmaceuticals stock opened at $54.75 on Friday. Eton Pharmaceuticals, Inc. has a 1 year low of $14.27 and a 1 year high of $66.37. The firm has a market cap of $1.56 billion, a price-to-earnings ratio of 144.08 and a beta of 0.90. The company has a 50-day moving average of $55.61 and a 200 day moving average of $40.04. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.52 and a quick ratio of 1.30.

Eton Pharmaceuticals (NASDAQ:ETON) last posted its quarterly earnings data on Thursday, August 13th. The company reported $0.43 EPS for the quarter, topping the consensus estimate of $0.19 by $0.24. The business had revenue of $37.59 million for the quarter, compared to analyst estimates of $27.11 million. Eton Pharmaceuticals had a net margin of 12.02% and a return on equity of 40.13%. As a group, sell-side analysts anticipate that Eton Pharmaceuticals, Inc. will post 1.13 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ETON has been the topic of several recent research reports. Zacks Research upgraded shares of Eton Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, August 24th. HC Wainwright upped their target price on shares of Eton Pharmaceuticals from $65.00 to $70.00 and gave the company a “buy” rating in a report on Friday, August 14th. Weiss Ratings raised shares of Eton Pharmaceuticals from a “sell (d-)” rating to a “hold (c)” rating in a report on Tuesday, September 22nd. Craig Hallum increased their price target on shares of Eton Pharmaceuticals from $40.00 to $62.00 and gave the stock a “buy” rating in a research report on Tuesday, July 28th. Finally, B. Riley Financial reiterated a “buy” rating and set a $70.00 price target (up from $40.00) on shares of Eton Pharmaceuticals in a research note on Friday, August 14th. Four investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $67.50.

Institutional Investors Weigh In On Eton Pharmaceuticals

Several large investors have recently added to or reduced their stakes in ETON. EcoR1 Capital LLC increased its stake in Eton Pharmaceuticals by 7.0% in the 1st quarter. EcoR1 Capital LLC now owns 2,171,938 shares of the company’s stock worth $53,603,000 after buying an additional 141,394 shares during the period. BlackRock Inc. purchased a new stake in Eton Pharmaceuticals in the 2nd quarter valued at about $68,629,000. Nantahala Capital Management LLC purchased a new stake in Eton Pharmaceuticals in the 2nd quarter valued at about $42,569,426. Pillsbury Lake Capital LLC purchased a new stake in Eton Pharmaceuticals in the 2nd quarter valued at about $14,015,083. Finally, Panoramic Capital LLC bought a new position in Eton Pharmaceuticals in the 2nd quarter worth about $7,537,000. 27.86% of the stock is owned by institutional investors.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, acquiring, and commercializing treatments for rare diseases and other underserved patient populations. The company’s strategy includes advancing proprietary product candidates and obtaining rights to established medicines that can address unmet medical needs.

Eton’s portfolio has included products such as Eprontia (topiramate) oral solution for certain seizure disorders and migraine prevention, Biorphen (phenylephrine hydrochloride) injection for the treatment of clinically important hypotension, and specialty medicines used in the management of rare metabolic and endocrine conditions.